| 名稱 | ADCP Bioassay Effector Cell FcγRIIa （R variant） -N |
| 型號 | CBP74004 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | ADCP Bioassay Effector Cell FcγRIIa （R variant） -NFAT/Jurkat，母細(xì)胞：Jurkat，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 國內(nèi)研究者Cell Research：韓春雨NgAgo有效
- 研究發(fā)現(xiàn)氣候可能決定人的鼻子形狀
- 腫瘤細(xì)胞到底是如何“轉(zhuǎn)移”的呢？
- 第四代ALK激酶抑制劑篩選模型
- 羅氏乳腺癌新藥獲英國NICE批準(zhǔn)用于HER2乳腺癌新輔助治療
- 5月是黑色素瘤意識月，盤點(diǎn)黑色素瘤研究進(jìn)展
- NIPT標(biāo)準(zhǔn)品-助力無創(chuàng)產(chǎn)前檢測
- 人結(jié)腸癌細(xì)胞株的細(xì)胞形態(tài)是不太規(guī)則的三角形
- 喝熱茶或使食管癌風(fēng)險(xiǎn)增加5倍
- BTLA細(xì)胞篩選模型簡介
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74004ADCP Bioassay Effector Cell FcγRIIa （R variant） -N
- 詳細(xì)內(nèi)容
| CBP74004 | |
| I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages. | |
| II. Description | |
Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Arginine variant.
| |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-FcγRIIa |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | N/A |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+400ug/ml hygromycin |
| Storage: | Liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
| |
Figure 1.Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant. | |
Figure 2：Detect Luciferase assay by Promega Bright-Glo Luciferase Assay System. ADCP Bioassay Effector Cell FcγRIIa (R variant) -NFAT/Jurkat cells were stimulated by FcγRIIa (R variant), the S/B was 29.3-fold. | |
員_a.png)